You Might Like
Bharat Biotech seeks DCGI nod for phase-3 study of intra-nasal Covid vaccine as booster dose"Bharat Biotech has put in an application seeking permission to conduct a study titled 'A Phase 3 Study to Evaluate the Safety and Immunogenicity of BBV154 and BBV152 as third dose (booster) to..IndiaTimes - Published | |
As Omicron fear intensifies, Serum Institute of India seeks DCGI's approval for Covishield booster shotRecently, Kerala, Rajasthan, Karnataka, and Chhattisgarh have also urged the Centre to decide on allowing booster doses of the COVID-19 vaccine.DNA - Published Also reported by •IndiaTimes | |
Bharat Biotech gets DCGI nod for shelf-life extension of its COVID-19 vaccine CovaxinBharat Biotech had submitted its data to the drug regulator and sought a shelf-life extension for its vaccine.DNA - Published | |
We are waiting for DCGI approval for children's Covid-19 vaccine: Bharat Bitoech ChairmanChairman and Managing Director of Bharat Biotech, Dr. Krishna Ella on Saturday said that they are waiting for approval from the Drugs Controller General of India (DCGI) for the Covid-19 vaccine for..IndiaTimes - Published | |
Covaxin's approval for children aged 2-18 years under experts' opinion, evaluation: SourcesThe final approval for Bharat Biotech's Covaxin for children aged 2-18 years is under experts opinion and evaluation, stated Government sources on Thursday. Earlier on Tuesday, official sources had..IndiaTimes - Published | |
AstraZeneca Pharma India gets DCGI nod to import, market Selumetinib capsulesIndiaTimes - Published | |
Covaxin kids trial over, Bharat Biotech to submit data to DCGI next weekIndiaTimes - Published | |
Sputnik Light COVID-19 vaccine gets DCGI nod for Phase 3 trials in IndiaEarlier in the month of April, the two-dose version of the vaccine, Sputnik V, was approved for 'emergency use' by the DCGI.DNA - Published Also reported by •IndiaTimes | |
Hetero’s Tocilizumab biosimilar gets DCGI nod for hospitalised Covid-19 patientsIndiaTimes - Published | |
DCGI nod to phase-I clinical trial of Covid-19 vaccine of Reliance Life SciencesIndiaTimes - Published | |
A momentous feat: PM Narendra Modi after Zydus Cadila's Covid vaccine gets emergency use authorisationThe department of biotechnology on Friday said indigenously developed Zydus Cadila Covid-19 vaccine ZyCoV-D has received approval for emergency use authorisation from the Drug Controller General of..IndiaTimes - Published | |
Zydus Cadila's ZyCoV-D vaccine gets DCGI nod for emergency use for adults, children above 12 yrsThe company said it plans to manufacture 100 million to 120 million doses of ZyCoV-D annually and has started to stockpile the vaccine.DNA - Published | |
DCGI gives nod to conduct study on mixing Covaxin, CovishieldThe Drugs Controller General of India (DCGI) has given approval to conduct a study on mixing Covaxin and Covishield vaccines. The research study will be done by Christian Medical College, Vellore, said..IndiaTimes - Published | Permission granted to CMC Vellore to mix vaccine doses for research study: Dr V K PaulDCGI has approved a proposal from the CMC Vellore to carry out trials on the mixed use of COVID-19 vaccines, Covishield and Covaxin in people.DNA - Published |
DCGI likely to approve Zydus Cadila's vaccine for children above 12 yearsZydus Cadila's COVID-19 vaccine, ZyCov-D, is a three-dose, intradermal vaccine which is applied using the PharmaJet needle-free systemDNA - Published | Zydus seeks nod for world’s first plasmid DNA Covid vaxHomegrown healthcare and pharmaceutical major Zydus Cadila has applied for emergency use authorisation (EUA) to the office of the Drug Controller General of India for ZyCoV-D, its plasmid DNA vaccine..IndiaTimes - Published |
DCGI gives emergency use nod to Moderna’s vaccineIndian pharma major Cipla will “facilitate” the import of Covid vaccines donated by US biotech major Moderna, possibly in the near future, under licence for restricted use by India’s drug..IndiaTimes - Published | Cipla gets DCGI nod to import Moderna's COVID-19 vaccineIn a boost to India's fight against coronavirus, the Drug Controller General of India (DCGI) has approved the emergency use of Moderna Covid-19 vaccine in India.DNA - Published |
Cipla gets DCGI nod to import Moderna's Covid vaccine for restricted emergency use in India: SourcesIndia's drug regulator DCGI has granted permission to Mumbai-based pharmaceutical company Cipla to import Moderna's Covid-19 vaccine for restricted emergency use in the country, official sources said..IndiaTimes - Published | Bharat Biotech has submitted Covaxin's Phase III trial data to DCGI: Govt sourcesIndiaTimes - Published |
Biophore seeks EUA from DCGI for Aviptadil inhalation for Covid-19 treatmentIndiaTimes - Published | COVID-19: DCGI approves Serum Institute to manufacture Sputnik V vaccine in IndiaSII has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow in Russia for developing Sputnik V.DNA - Published |
Serum Institute gets DCGI's nod to manufacture Covid jab Sputnik V in IndiaIndiaTimes - Published Also reported by •DNA | DCGI waiver likely to bring foreign vaccines like Pfizer, Moderna a step closer​In a letter, DCGI Chief VG Somani letter said that this will be applicable for vaccines that have already been approved for restricted use by the US FDA, EMA, UK MHRA, PMDA Japan or listed for..IndiaTimes - Published |
COVID-19: Big relief for foreign vaccine makers as DCGI exempts post-approval bridging trialsCipla, which has been looking to commit USD 1 billion into bringing Moderna's single-dose mRNA booster vaccine to India, also requested an exemption.DNA - Published | Covaxin trial for 2-18 yrs age group to begin in 10-12 days, govt saysTrial of Bharat Biotech's Covaxin in the 2-18 years age group is likely to begin in the next 10-12 days., a govt official said. The vaccine received DCGI approval for the trials last week. 1.8% of..IndiaTimes - Published |
COVID-19: Covaxin gets approval for phase 2-3 clinical trials for 2-18 age group, to begin in next 10-12 daysPhase 2-3 clinical trials of Covaxin, which has been approved by the DCGI for in the age group of 2 to 18 years, will begin in 10 to 12 days.DNA - Published | DGCI gives nod for Covaxin Phase II/III trials on 2-18 year oldsThe Indian drugs regulator, the Drugs Controller General of India (DCGI) has granted its approval to indigenously developed Covid-19 vaccine Covaxin’s developer Bharat Biotech for conducting Phase..IndiaTimes - Published |
Covid-19: DCGI approves phase 2, 3 clinical trials of Covaxin on children aged 2 to 18 yearsThe Drugs Controller General of India (DCGI) approved phase 2 and 3 clinical trials of Bharat Biotech's Covaxin vaccine for the age group of 2 to 18 years, the ministry of health and family welfare..IndiaTimes - Published Also reported by •DNA | Potential cancer drug repurposed for Covid-19 by DRDO, Dr Reddy's gets DCGI nod for emergency useA potential cancer drug repurposed for Covid-19 treatment -- 2-deoxy-D-glucose (2-DG) – has received the Drugs Controller General of India (DCGI) nod for emergency use as adjunct therapy for..IndiaTimes - Published |
DCGI approves anti-Covid drug developed by DRDO for emergency useThe Drugs Controller General of India’s (DCGI) has approved an anti-Coviddrug - 2-deoxy-D-glucose (2-DG) for emergency use. This has been developed by the Institute of Nuclear Medicine and Allied..IndiaTimes - Published Also reported by •DNA | |
